| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0735-1097(00)00796-8 |
| P698 | PubMed publication ID | 10987608 |
| P2093 | author name string | H Horie | |
| K Maeda | |||
| M Kinoshita | |||
| M Ohnishi | |||
| A Wada | |||
| M Hayashi | |||
| T Matsumoto | |||
| Y Sugimoto | |||
| M Fujii | |||
| T Tsutsui | |||
| N Mabuchi | |||
| M Sawaki | |||
| T Tsutamoto | |||
| P2860 | cites work | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 |
| Captopril in heart failure. A double blind controlled trial | Q36753945 | ||
| Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass | Q36839438 | ||
| Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system | Q37087344 | ||
| Mineralocorticoids, hypertension, and cardiac fibrosis | Q40337147 | ||
| Aldosterone escape during ACE inhibitor therapy in chronic heart failure | Q41016806 | ||
| Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients | Q42547596 | ||
| Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction | Q48657782 | ||
| Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension | Q49168698 | ||
| Antihypertensive Therapy with MK 4211 | Q62090301 | ||
| Biological determinants of aldosterone-induced cardiac fibrosis in rats. | Q64910858 | ||
| Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor | Q67494059 | ||
| Angiotensin II-forming pathways in normal and failing human hearts | Q68452884 | ||
| ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES) | Q71193550 | ||
| The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction | Q71550904 | ||
| Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart | Q71844423 | ||
| Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis | Q72198058 | ||
| Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone | Q72819723 | ||
| Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) | Q73164612 | ||
| Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation | Q74230761 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | congestive heart failure | Q19000661 |
| P304 | page(s) | 838-844 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure | |
| P478 | volume | 36 |
| Q28258044 | A reappraisal of loop diuretic choice in heart failure patients |
| Q34623717 | Aldosterone receptor blockade in the management of heart failure |
| Q34796261 | Aldosterone synthesis in the brain contributes to Dahl salt-sensitive rat hypertension |
| Q35214052 | Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone |
| Q57689089 | Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction |
| Q35071304 | Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor |
| Q42795421 | Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure |
| Q43573505 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure |
| Q42968904 | Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE". |
| Q36203050 | Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms |
| Q34182202 | Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. |
| Q35660795 | Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system |
| Q44430971 | Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard |
| Q43636281 | Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction |
| Q43787206 | Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarctio |
| Q35906989 | The multifaceted mineralocorticoid receptor |
| Q35580139 | Toward a broader understanding of aldosterone in congestive heart failure |
Search more.